Clinical Trials Browser

Recruiting × ribociclib × 90 days × Clear all

NCT05203172 2026-03-18

The FLOTILLA Study: Providing Continued Access to The Study Medicines Encorafenib and Binimetinib for Participants in Prior Clinical Trials

Phase 4 Recruiting

Other solid neoplasm

Solid Tumors

NCT06377852 2026-03-18

The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study

Phase 3 Recruiting

Breast Neoplasms

NCT06625775 2026-03-18

Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors

Phase 1 Recruiting

BreastGastrointestinalThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasm Metastasis, Colorectal Neoplasms

NCT03424005 2026-03-16

Morpheus-panBC

Phase 1/2 Recruiting

Breast Neoplasms

NCT04802759 2026-03-16

A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer

Phase 1/2 Recruiting

Neoplasm Metastasis

NCT06930859 2026-03-16

ELEGANCE

Breast Neoplasms

NCT07085767 2026-03-16

OPERA-02

Phase 3 Recruiting

Breast Neoplasms

NCT07237256 2026-03-16

NoLEEta

Phase 3 Recruiting

Breast Neoplasms

NCT06065748 2026-03-09

A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)

Phase 3 Recruiting

Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer

NCT07405801 2026-03-09

A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus Fulvestrant in Participants With Advanced Breast Cancer

Phase 2 Recruiting

Breast Neoplasms

NCT07174336 2026-03-06

A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)

Phase 3 Recruiting

Breast Neoplasms, Neoplasm Metastasis

NCT05843253 2026-03-04

Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant

Phase 2 Recruiting

Diffuse Intrinsic Pontine Glioma, Astrocytoma, Brain Neoplasms, Glioblastoma, Glioma

NCT06830720 2026-03-03

CAROLEEN

Breast Neoplasms

NCT05768139 2026-03-02

PIKALO-1

Phase 1/2 Recruiting

BreastGynecologicHead & Neck

Squamous Cell Carcinoma of Head and Neck, Breast Diseases, Breast Neoplasms, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Neoplasms, Neoplasms by Site, Hereditary Sensory and Autonomic Neuropathies, Ovarian Neoplasms, Endometrial Neoplasms

NCT05827081 2026-03-02

Adjuvant WIDER

Phase 3 Recruiting

Breast Neoplasms, Breast Neoplasms, Male

NCT06760637 2026-03-02

FourLight-3

Phase 3 Recruiting

Unilateral Breast Neoplasms, Breast Neoplasms, Recurrence

NCT05467891 2026-02-27

RaPhLRR

Phase 2 Recruiting

Locoregional Recurrence

NCT06188520 2026-02-24

CYCAD-1

Phase 1/2 Recruiting

BreastGynecologic

ER+ HER2- Advanced Breast Cancer

NCT06905301 2026-02-20

IMPULSE

Breast Neoplasms

NCT05238922 2026-02-10

Study of INCB123667 in Subjects With Advanced Solid Tumors

Phase 1 Recruiting

BreastGastrointestinalGynecologic

Carcinoma, Ovarian Epithelial, Breast Neoplasms, Digestive System Neoplasms

NCT06797531 2026-02-04

NISLEESA

Breast Neoplasms

NCT05996107 2026-01-28

Study of Ribociclib Administered Concurrently With Postoperative Radiation Therapy in Patients With High-Risk, HR+/HER2- Breast Cancer

Phase 1 Recruiting

Breast Neoplasms

NCT02813135 2026-01-16

ESMART

Phase 1/2 Recruiting

Neoplasms

NCT07002177 2026-01-07

A Phase Ib/II Study to Evaluate Multiple Combination Therapies of FWD1802 in Patients With ER+/HER2- BC

Phase 1/2 Recruiting

Breast Neoplasms

NCT06726148 2026-01-06

Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and Other Advanced Solid Tumors

Phase 1/2 Recruiting

Breast Neoplasms